DistillerSR Launches Smart Screening for Research Teams

DistillerSR, a leader in AI-enabled literature review automation and evidence management, has launched a new feature called Smart Screening. This tool provides pharmaceutical, medical device, and research teams with a fully automated, AI-enabled system for screening titles and abstracts of published research, ensuring unprecedented productivity and regulatory compliance.

Smart Screening is integrated into the DistillerSR platform, enhancing the company's existing capabilities with a purpose-built GenAI module. This module can process up to 100,000 abstracts per run, making it an invaluable tool for teams grappling with the growing volume of published research. The technology allows for both fully automated workflows and human-in-the-loop approaches, offering flexibility to meet the varying needs of different projects.

According to Peter O'Blenis, CEO of DistillerSR, "Smart Screening brings the same trusted technology used in our Smart Evidence Extraction module to title and abstract screening. These capabilities are fundamentally reshaping evidence generation, dramatically accelerating research, regulatory, and safety practices."

The new feature boasts several key advantages. It offers full automation, ensuring efficient and consistent processing of abstracts without the need for extensive setup. Additionally, the human-in-the-loop workflow allows expert reviewers to maintain oversight of every AI decision, particularly in high-stakes regulatory submissions. DistillerSR emphasizes that Smart Screening works without any model preparation or training, making it accessible to a wide range of users.

One of the standout features of Smart Screening is its secondary AI error checking, which leverages an independent AI to validate the screening decisions made by the primary AI. This ensures a higher level of accuracy and reliability in the screening process. The tool also offers regulatory-grade auditability, providing a fully traceable rationale for every inclusion and exclusion decision. This feature supports defensible regulatory submissions and notified body audits, ensuring that the data generated is transparent and compliant.

Dr. Sarah Thompson, a researcher at a leading pharmaceutical company, commented on the impact of Smart Screening, "With the exponential growth in published research, it's crucial to have tools that can efficiently screen vast volumes of data. Smart Screening significantly enhances our ability to manage and analyze evidence-based research, streamlining our processes and ensuring we stay ahead of the curve."

DistillerSR's product line now offers a comprehensive suite of tools for evidence generation, including Smart Screening, Smart Evidence Extraction, and other AI-driven modules. The company is committed to helping research teams navigate the complexities of the growing body of scientific literature, enabling them to focus on advancing medical research and bringing life-changing products to market more quickly.

With the launch of Smart Screening, DistillerSR continues to set the standard for AI-driven solutions in the pharmaceutical and medical device industries. By integrating advanced AI capabilities into their platform, the company is empowering researchers to work more efficiently and effectively, ultimately benefiting patients and the broader healthcare community.